742,574 Shares in Evolus, Inc. (NASDAQ:EOLS) Bought by Tri Locum Partners LP

Tri Locum Partners LP bought a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 742,574 shares of the company’s stock, valued at approximately $8,198,000. Evolus makes up 1.7% of Tri Locum Partners LP’s investment portfolio, making the stock its 22nd largest holding. Tri Locum Partners LP owned about 1.17% of Evolus at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. KBC Group NV purchased a new position in shares of Evolus during the 4th quarter valued at about $49,000. IFP Advisors Inc lifted its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus during the fourth quarter valued at approximately $106,000. Quantbot Technologies LP bought a new position in shares of Evolus in the fourth quarter worth approximately $118,000. Finally, Tradition Wealth Management LLC increased its stake in shares of Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Insider Transactions at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the sale, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the transaction, the insider now owns 508,619 shares of the company’s stock, valued at approximately $6,306,875.60. This represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock valued at $794,369 in the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. BTIG Research assumed coverage on Evolus in a research note on Thursday, April 17th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Evolus has a consensus rating of “Buy” and an average target price of $23.75.

Evolus Price Performance

NASDAQ:EOLS opened at $11.65 on Friday. The company has a market capitalization of $740.79 million, a P/E ratio of -12.80 and a beta of 0.97. The business’s 50-day moving average is $12.25 and its 200 day moving average is $12.92. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.